<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967317</url>
  </required_header>
  <id_info>
    <org_study_id>E02-OSM-AS-01-08</org_study_id>
    <nct_id>NCT00967317</nct_id>
  </id_info>
  <brief_title>Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.</brief_title>
  <acronym>E02OSMAS0108</acronym>
  <official_title>Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Osorio de Moraes Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Osorio de Moraes Ltda.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and tolerability of Auris-Sedina in the symptomatic control of
      otalgy in patients with and without acute external otitis compared with use of Otosynalar®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III open Study, multicenter, prospective, randomized entrance of a total of 188
      patients, 94 patients will receive medication test and 94 patients will receive Otosynalar®.

      Patients will be assessed until the clinical condition has been resolved or a maximum of 3
      days.

      188 patients of either gender or race, who have at least two of the following symptoms: pain,
      discharge, tinnitus, ear fullness, subjective hearing loss temporary dizziness or vertigo.
      And with a clinical or non-acute external otitis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogic Scale, by clinical examination and opinion of the investigator.</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Of adverse events related to study medication by the Naranjo Algorithm.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Otitis</condition>
  <condition>Efficacy</condition>
  <condition>Tolerability</condition>
  <arm_group>
    <arm_group_label>Auris-Sedina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.
The medication should be used for a maximum of 3 days when they should return to the doctor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Otosynalar®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Auris-Sedina</intervention_name>
    <description>Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.
The medication should be used for a maximum of 3 days when they should return to the doctor.</description>
    <arm_group_label>Auris-Sedina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Otosynalar®</intervention_name>
    <description>Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.</description>
    <arm_group_label>Otosynalar®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with otalgy or not, with acute external otitis ;

          -  Patients with at least two symptoms of otalgy (pain, discharge, tinnitus, ear
             fullness, subjective hearing loss temporary dizziness or vertigo) with the Visual
             Analogic Scale score between 4 and 8 (mild to moderate);

          -  The patient must present otalgia in one ear;

          -  Children above 6 years of age;

          -  Adults over 18 years of age;

          -  Patients who consent to participate in the study;

          -  Patients who are female and are of childbearing age should use reliable method of
             contraception and have negative pregnancy test.

        Exclusion Criteria:

          -  Patients with sensitivity to any component of the formula;

          -  Patients pregnant or lactating;

          -  Non visualization of the tympanic membrane of obstruction by cerumen;

          -  Patients with evidence of any wound or scratch on the ear (ulcerative lesion);

          -  Patients who are making use of any other medication that might interfere with the
             evaluation of effectiveness of study (such as antibiotics, antiinflammatory, solutions
             ear);

          -  Patients who have severe classification in the Visual Analogic Scale score 9 or 10 in
             any of the symptoms listed in the questionnaire;

          -  Patients with otalgy not otological origin;

          -  Patients with otitis, except acute external otitis ;

          -  Patients who have epiglottitis;

          -  The patient with infection;

          -  Patients who can not follow the procedures clarified in this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Fiss</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagoberto Brandão</last_name>
    <phone>55 11 3673 3763</phone>
    <email>dagoberto@phcbrasil.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>August 25, 2009</last_update_submitted>
  <last_update_submitted_qc>August 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maria Angelina Nardy Mattos</name_title>
    <organization>Laboratórios Osório de Moraes Ltda.</organization>
  </responsible_party>
  <keyword>Auris-Sedina</keyword>
  <keyword>Otitis</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

